Bionano Genomics, Inc. 8-K

What Happened
Bionano Genomics, Inc. announced and filed an 8-K (Item 2.02) on March 23, 2026 reporting its financial results for the fourth quarter ended December 31, 2025. The company issued a press release with the quarterly results, and the full text of that press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: March 23, 2026.
• Reporting period: Fourth quarter ended December 31, 2025.
• Disclosure format: Press release attached as Exhibit 99.1; Inline XBRL (Item 9.01, Exhibit 104) included for the cover page.
• Signed by R. Erik Holmlin, Ph.D., President and Chief Executive Officer (also the principal executive and financial officer).

Why It Matters
This 8-K makes Bionano’s Q4 2025 earnings and related financial information publicly available; investors should read the attached press release for revenue, profitability, cash position, and any guidance or business updates. The filing does not report any other material events (such as executive departures or transactions), so the press release is the primary source for this quarter’s financial details.